Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05860348 · ClinicalTrials.gov registry record
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
A clinical trial, sponsored by CVRx.
- Terminated
- Registry status
- 5
- Enrollment target
NCT05860348: Clinical Trial study, sponsored by CVRx.
NCT05860348 is a clinical trial that was terminated before completion, run by CVRx. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05860348 was terminated before completion, sponsored by CVRx.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
Interventions
- DEVICE Barostim™ System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2024-12-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05860348
The ClinicalTrials.gov registry entry for NCT05860348 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CVRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Barostim™ System is the first listed.
NCT05860348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05860348 about?
NCT05860348 is a clinical study titled "Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence". The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
What is the current status of trial NCT05860348?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2023-07-25. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT05860348?
The interventions under investigation include: Barostim™ System (DEVICE).
Who is sponsoring clinical trial NCT05860348?
This trial is sponsored by CVRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.